主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
BNTC
#2504
Benitec Biopharma Inc. Common Stock
10.900
0
-0.05%
版块:
基础:
利润货币:
日范围
年范围
日变化
-0.05%
每月变动
-12.03%
6个月变化
-34.38%
年变化
-34.38%
前一天收盘价
10.905
0
Open
10.900
0
Bid
Ask
Low
10.900
0
High
10.900
0
交易量
21
市场
股票
医疗保健
BNTC
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
480.69 K
480.69 K
2.55 M
10.56 M
26.25 M
—
Valuation ratios
Enterprise value
—
—
—
25.78 M
209.43 M
1.09 B
Price to earnings ratio
—
—
—
-1.32
-11.14
-55.92
Price to sales ratio
—
—
—
—
507.36
—
Price to cash flow ratio
—
—
—
-1.52
-17.96
-73.48
Price to book ratio
—
—
—
0.62
4.35
7.36
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.65
3.05
4.38
0.42
0.38
0.33
Return on equity %
0.69
6.32
96.84
0.46
0.39
0.35
Return on invested capital %
4 482.53
3 514.9
3 266.88
3 003.67
6 764.5
—
Gross margin %
100
100
100
—
100
—
Operating margin %
23.04 K
24.46 K
25.44 K
—
5 001.8
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
23.53 K
24.94 K
26.08 K
—
4 540.96
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
15.05
1.9
0.94
10.49
54.67
184.12
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.01
0.01
0
0.01
-0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
33.08
12.99
4.78
0.65
0.47
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
8.53
1.8
12.54
2.7
11.77
Net current asset value per share
—
10.03
2.69
12.73
2.72
11.83
Tangible book value per share
—
6
0.15
11.64
2.69
11.54
Working capital per share
—
4.76
-0.18
11.51
2.67
11.49
Book value per share
—
6
0.15
11.64
2.69
11.54
新闻
Gentherapie-Daten stützen Benitec-Aktie: Rating bestätigt
Benitec BioPharma stock rating maintained on gene therapy data
Benitec to present BB-301 gene therapy study results in March
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Benitec BioPharma: Citizens bestätigt Einstufung "Market Outperform"
Citizens reiterates Market Outperform rating on Benitec BioPharma stock
Benitec BioPharma: TD Cowen bestätigt Kaufempfehlung nach starken OPMD-Studiendaten
Benitec BioPharma stock maintains Buy rating at TD Cowen on strong OPMD data
Benitec BioPharma: Baird bestätigt "Outperform"-Rating und Kursziel von 30 US-Dollar
Baird reiterates Outperform rating on Benitec BioPharma stock at $30 target
Benitec’s gene therapy shows durable results in OPMD patients
Monday’s Insider Moves: Dolphin CEO’s Big Bet Amid Notable Sells